Grant: Engage Grants Program
Ryerson University
$25,000.00
Molecular/genetic data to innovate Cyclica's in silico pipeline
EF 2019-20
Résumé
Cyclica Inc. is an internationally recognized, Toronto-based biotechnology company. Cyclica's goal is to reshape drug discovery by identifying high-activity and highly-specific protein inhibitors. Proteins are a main building block of cells, and are also used in enzymatic reactions outside of cells. Specifically inhibiting unwanted or non-specific protein activities has tremendous potential and impact across many industries including pharmaceuticals, agriculture, and chemical synthesis. Using computational biophysics and artificial intelligence, Cyclica has developed innovative software-as-service models to target a specific protein activity of interest. Their two products meet this goal by: 1) developing a new small molecule initiator (LigandDesignTM), or, 2) identifying a pre-existing compound to test for new applications (LigandExpressTM, Matchmaker). The Sabatinos lab is collaborating with Cyclica to test and refine their Matchmaker technology for new uses. Dr. Sarah Sabatinos (Ryerson University, Toronto) will use yeast cells to test how Matchmaker can help to repurpose already-approved drugs. The Sabatinos lab will use drug sensitivity tests and microscopy to clearly define the effects of compounds selected by Cyclica's technology, and compared to the desired/predicted effects. Our combined goal is to refine Cyclica's compound-selection methods against data from a non-human cell model, expanding the potential utility. We aim to develop a ""Repurposing Index"" to guide small molecule choice in drug repurposing studies. This work is important to promote training and improve biotechnology, drug discovery, and predictive computational tools in Canada.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
544126-2019
Name nom
Sabatinos, Sarah
Department département
Chemistry and Biology
Organization id
43
Institution établissement
Ryerson University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2019
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
507
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Industrial chemicals (solvents, resins)
Area of application fr
Produits chimiques industriels (solvants, résines)
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Molecular/genetic data to innovate Cyclica's in silico pipeline
Keyword
NSERC
Application summary
Cyclica Inc. is an internationally recognized, Toronto-based biotechnology company. Cyclica's goal is to reshape drug discovery by identifying high-activity and highly-specific protein inhibitors. Proteins are a main building block of cells, and are also used in enzymatic reactions outside of cells. Specifically inhibiting unwanted or non-specific protein activities has tremendous potential and impact across many industries including pharmaceuticals, agriculture, and chemical synthesis. Using computational biophysics and artificial intelligence, Cyclica has developed innovative software-as-service models to target a specific protein activity of interest. Their two products meet this goal by: 1) developing a new small molecule initiator (LigandDesignTM), or, 2) identifying a pre-existing compound to test for new applications (LigandExpressTM, Matchmaker). The Sabatinos lab is collaborating with Cyclica to test and refine their Matchmaker technology for new uses. Dr. Sarah Sabatinos (Ryerson University, Toronto) will use yeast cells to test how Matchmaker can help to repurpose already-approved drugs. The Sabatinos lab will use drug sensitivity tests and microscopy to clearly define the effects of compounds selected by Cyclica's technology, and compared to the desired/predicted effects. Our combined goal is to refine Cyclica's compound-selection methods against data from a non-human cell model, expanding the potential utility. We aim to develop a ""Repurposing Index"" to guide small molecule choice in drug repurposing studies. This work is important to promote training and improve biotechnology, drug discovery, and predictive computational tools in Canada.